SAN DIEGO–(BUSINESS WIRE)–Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that it is now registered as an approved vendor of insulin pumps and supplies under the Assistive Devices Program (ADP) in Ontario, Canada. The t:slim X2 insulin pump features Dexcom G5® Mobile continuous glucose monitoring (CGM) integration,1 making it the only CGM-integrated insulin pump approved in Canada for making daily diabetes treatment decisions without fingersticks.2
“This registration is meaningful, as approximately 40 percent of people living with type 1 diabetes in Canada reside in Ontario and are now able to obtain reimbursement for the t:slim X2 insulin pump,” said John Sheridan, president and CEO of Tandem Diabetes Care. “We’ve seen a high level of interest from people with diabetes in Canada, where insulin pump options have been limited in recent years. By reducing a financial barrier, this registration provides more people access to our exciting technology as a new option for insulin therapy management.”
read more –> CanTechLetter.com
